2000
DOI: 10.1021/jm000078q
|View full text |Cite
|
Sign up to set email alerts
|

Design and Synthesis of Pyrrolidine-5,5-trans-lactams (5-Oxo-hexahydro-pyrrolo[3,2-b]pyrroles) as Novel Mechanism-Based Inhibitors of Human Cytomegalovirus Protease. 1. The α-Methyl-trans-lactam Template

Abstract: Mechanism-based inhibitors of human cytomegalovirus (HCMV) protease have been designed based on the pyrrolidine-5,5-trans-lactam ring system. New routes to the beta-methyl-, desmethyl-, and alpha-methyl-pyrrolidine-5,5-trans-lactam templates have been developed from 2,4-diaminobutyric acid. ESI/MS studies have shown that these inhibitors can bind covalently and reversibly to the viral enzyme in a time-dependent manner by a mechanism which is consistent with acylation of HCMV deltaAla protease at the active sit… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
39
0

Year Published

2004
2004
2023
2023

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 46 publications
(39 citation statements)
references
References 19 publications
0
39
0
Order By: Relevance
“…In related work, bicyclic lactam derived 'trans-lactam' inhibitors, ultimately derived from more complex natural products, were developed as potent inhibitors of nucleophilic serine proteases [101][102][103][104] (though these have not been d eveloped as PBP/serine β-lactamase inhibitors).…”
Section: Future Science Groupmentioning
confidence: 99%
See 2 more Smart Citations
“…In related work, bicyclic lactam derived 'trans-lactam' inhibitors, ultimately derived from more complex natural products, were developed as potent inhibitors of nucleophilic serine proteases [101][102][103][104] (though these have not been d eveloped as PBP/serine β-lactamase inhibitors).…”
Section: Future Science Groupmentioning
confidence: 99%
“…(B) Examples of 'new' β-lactam scaffolds also show promise, but they have not been commercially developed (AM-112 (10.9) [154] and LK-157 (10.10) [155]). (C) Examples of natural product derived non-β-lactam type scaffolds which are inhibitors of nucleophilic serine enzymes (trans-lactams (10.11) [101] and a related natural product from Lantana camara (10.11) [156], and the strigolactones (10.13) [157]); derivatives of these could be pursued as penicillin-binding protein/β-lactamase inhibitors. The road to avibactam -the first clinically useful non-β-lactam working somewhat like a β-lactam Review structural water are close to the ester link with the nucleophilic serine (Ser-70); the complex is apparently stabilized by interactions with the Lys-73:Ser-130 and Glu-166:Asn-170 'dyads' which are important in catalysis.…”
Section: Avibactam Mode Of Actionmentioning
confidence: 99%
See 1 more Smart Citation
“…In the synthesis of hydroxy analogue 40 the published procedure by Borthwick et al was used to get hold of the orthogonally protected building block 37. [20] In this procedure, the amino acid moiety of 36 was temporarily protected via formation of a copper complex, the benzyloxycarbonyl (Z) group was introduced, and the copper complex was destroyed afterward with EDTA. Finally, the tert-butoxycar- bonyl (Boc) group was introduced, and the desired material was isolated in 72 % overall yield.…”
Section: Lead Optimization Of Macrocyclic Aminopyrimidinesmentioning
confidence: 99%
“…Most of these inhibitors contain classical serine protease inhibitor motifs based on an activated carbonyl group such as peptidyl ketoamides, 8;9 as well as mechanism-based inhibitors such as oxazazinones 10;11 and pyrrolidine-5,5-trans-lactams. [12][13][14] Among these latter inhibitors, a series of monocyclic b-lactams 1 (compound 1a being the prototype) has resulted in highly potent derivatives in the isolated enzyme assay, but their efficacy in cell culture was quite limited, as for all described inhibitors of this enzyme. 15 This paper deals with the synthesis and evaluation of a series of new azetidinones 2, derived from phenylalanine, which were designed on the basis of the structure of the reported b-lactam inhibitors 16 and of the residues implicated in the active site of the HCMV protease.…”
mentioning
confidence: 99%